Syndax Pharmaceuticals, Inc
Price
OptionsOpen the Sheet →FilingsNewest: Form 4, insider tradeNov 12 →InsidersNo open-market buys. 4 insiders sold $2.9M, 4 of 10 sales on a 10b5-1 plan.→HoldersBlackRock 10.0%Kynam 8.9%Goldman Sachs 6.5%→Financing →PeersClosest companies: CHRS, VSTM, SMMT→
From the filings
Figures
- Revenue
- $289.7Mlast 12 months
- Net income
- −$209.5Mlast 12 months
- Operating cash flow
- −$220.6Mlast 12 months
- Cash and equivalents
- $135.9Mat the last balance sheet
- Total debt
- $344.1Mat the last balance sheet
- Shares outstanding
- 90.0M shareson issue
Filings, newest first
- Nov 124Insider trade
- Nov 1013GStake over 5%, passive
- Nov 210-QQuarterly report
- Nov 28-KResults of operations
- Oct 304Insider trade
- Aug 713GStake over 5%, passive
- Aug 410-QQuarterly report
- Aug 48-KResults of operations
- Jul 148-KOther events
- Jun 108-KMaterial agreement
- Feb 2610-KAnnual report